マサチューセッツ州における肺がんの臨床試験
マサチューセッツ州内の拠点で、肺がんに関する75件の研究が参加者を募集しています。
マサチューセッツ州内の都市
- Boston62件の研究
- Worcester11件の研究
- Somerville6件の研究
- Springfield5件の研究
- Quincy3件の研究
- Newton3件の研究
- Lynn3件の研究
- Lawrence3件の研究
公式研究テキスト（英語）
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
- Beverly Hospital, Beverly
- Boston Medical Center, Boston
- Beth Israel Deaconess Medical Center, Boston
- 他8件
被験者募集中第3相
18歳以上 · 全性別 · 2026/10/02更新 · NCT04267848The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
- Massachusetts General Hospital, Boston
- Dana Farber Cancer Institute, Boston
被験者募集中第1/2相
12歳以上 · 全性別 · 2026/10/02更新 · NCT04585750Distance-Based Exercise to Preserve Function and Prevent Disability
- Dana-Farber Cancer Institute, Boston
被験者募集中
18歳以上 · 全性別 · 2026/10/02更新 · NCT07059884Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial
- Tufts Medical Center, Boston
- Dana-Farber Cancer Institute at Boston Medical Center - Brighton, Brighton
- Dana-Farber Cancer Institute at Foxborough, Foxborough
- 他3件
被験者募集中第3相
70歳以上 · 全性別 · 2026/10/01更新 · NCT06096844Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer
- UMass Memorial Medical Center - University Campus, Worcester
被験者募集中第3相
18歳以上 · 全性別 · 2026/10/01更新 · NCT04181060Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Insitute, Boston
被験者募集中第1相
18歳以上 · 全性別 · 2026/10/01更新 · NCT06625775Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
- Beverly Hospital, Beverly
- Lahey Clinic, Burlington
- Addison Gilbert Hospital, Gloucester
- 他3件
被験者募集中第3相
18歳以上 · 全性別 · 2026/10/01更新 · NCT06498635Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC
- Dana-Farber Cancer Institute, Boston
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/30更新 · NCT06765109A Study of PHN-012 in Patients With Advanced Solid Tumors
- PHN-012-001 Site, Boston
被験者募集中第1相
18歳以上 · 全性別 · 2026/09/29更新 · NCT07127874A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
- Reliant Medical Group Inc, Worcester
被験者募集中第3相
18歳〜100歳 · 全性別 · 2026/09/25更新 · NCT05920356This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.
- Southcoast Centers for Cancer Care, Fairhaven
- Southcoast Centers for Cancer Care, Fall River
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/25更新 · NCT06758401A Registry for People With Lung Cancer
- Massachusetts General Hospital Cancer Center (Data Collection Only), Boston
- Brigham and Women's Hospital (Data Collection Only), Boston
被験者募集中観察研究
18歳以上 · 全性別 · 2026/09/24更新 · NCT06424327A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion
- Dana-Farber Cancer Institute, Boston
被験者募集中第2/3相
18歳以上 · 全性別 · 2026/09/23更新 · NCT07063745Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer
- Research Site, Boston
被験者募集中第2相
18歳〜95歳 · 全性別 · 2026/09/23更新 · NCT05061550Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
- Dana Farber Cancer Institute, Boston
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/09/22更新 · NCT06128551A Community Health Intervention to Improve Lung Cancer Screening Uptake in Community Health Centers
- Baystate Health, Springfield
被験者募集中健康なボランティア歓迎
50歳〜80歳 · 全性別 · 2026/09/22更新 · NCT07168629Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
- Dana-Farber Cancer Institute, Boston
被験者募集中第2/3相
18歳以上 · 全性別 · 2026/09/22更新 · NCT07100080A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS Mutations
- Massachusetts General Hospital - Main Campus, Boston
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/09/21更新 · NCT07629960Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
- Dana-Farber Cancer Institute, Boston
被験者募集中第1相
18歳以上 · 全性別 · 2026/09/17更新 · NCT07349537Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
- Dana-Farber Cancer Institute, Boston
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/09/16更新 · NCT05786924Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
- Dana Farber Cancer Institute, Boston
被験者募集中第1相
18歳以上 · 全性別 · 2026/09/10更新 · NCT06293898Stereotactic Brain-directed Radiation With or Without Aguix Gadolinium-Based Nanoparticles in Brain Metastases
- Brigham and Women's Hospital, Boston
- Dana Farber Cancer Institute, Boston
被験者募集中第2相
18歳以上 · 全性別 · 2026/09/09更新 · NCT04899908A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
- Massachusetts General Hospital, Boston
- University of Massachusetts Memorial Medical Center, Worcester
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/08更新 · NCT06793215A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
- Boston Medical Center, Boston
- Lahey Hospital & Medical Center, Burlington
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/08更新 · NCT06119581A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
被験者募集中第1相
18歳以上 · 全性別 · 2026/09/08更新 · NCT06561685AVENTINE-1: Study of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (AVZO-1418-1001)
- Avenzo Therapeutics Recruiting Site, Boston
被験者募集中第1/2相
18歳〜75歳 · 全性別 · 2026/09/04更新 · NCT07038343Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer
- Beth Israel Lahey Health - Lahey Hospital & Medical Center (LHMC), Lahey Clinic Medical Center, Burlington
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/01更新 · NCT06712355Investigating Hereditary Risk In Thoracic Cancers (INHERIT)
- Brigham and Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
被験者募集中観察研究
18歳以上 · 全性別 · 2026/08/26更新 · NCT05587439LEGACY: Lung Cancer Screening in Individuals With a Lung Cancer Family History-Protocol B
- Massachusetts General Hospital, Boston
被験者募集中観察研究
18歳以上 · 全性別 · 2026/08/25更新 · NCT07600801Practical Geriatric Assessment in Older Adults With Non-Small Cell Lung Cancer Undergoing Stereotactic Body Radiation Therapy
- Brigham and Women's Hospital, Boston
被験者募集中
65歳以上 · 全性別 · 2026/08/25更新 · NCT06987890Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer
- UMass Memorial Medical Center - University Campus, Worcester
被験者募集中第3相
18歳以上 · 全性別 · 2026/08/17更新 · NCT05624996InAdvance: Surveillance, Prevention, and Interception in a Population at Risk for Cancer
- Dana Farber Cancer Institute, Boston
被験者募集中観察研究健康なボランティア歓迎
全年齢 · 全性別 · 2026/08/17更新 · NCT05463796A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
- Massachusetts General Hospital Cancer Center, Boston
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/08/11更新 · NCT05592626Preliminary Efficacy of Different Exercise Training During Immunotherapy in Patients With Lung Cancer: The ENHANCE Trial
- Dana-Farber Cancer Institute, Boston
被験者募集中
18歳以上 · 全性別 · 2026/08/10更新 · NCT06026111Precise Exercise Regimen for Cancer Care (PERCC): A Pilot Study
- Dana-Farber Cancer Institute, Boston
被験者募集中
18歳以上 · 全性別 · 2026/08/05更新 · NCT07412041EQUAL: EGFR ctDNA QUantative Assessment for Lung Cancer Screening in Asian and Latinx Populations
- Beth Israel Deaconess Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
- Massachusetts General Hospital, Boston
- 他3件
被験者募集中健康なボランティア歓迎
40歳〜80歳 · 全性別 · 2026/07/15更新 · NCT06716580A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/07/15更新 · NCT05652686Ivonescimab Alone And With Carboplatin/Pemetrexed For NSCLC
- Massachusetts General Hospital, Boston
- Beth Israel Deaconess Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
被験者募集中第2相
18歳以上 · 全性別 · 2026/07/15更新 · NCT07405190Mobile Application to Improve Health-Related Outcomes in Patients With Advanced Lung Cancer
- Massachusetts General Hospital, Boston
被験者募集中
18歳以上 · 全性別 · 2026/07/13更新 · NCT06427954Study of NXP900 With Osimertinib in Subjects With Advanced, EGFR-Mutated Non-Small Cell Lung Cancer
- Massachusetts General Hospital, Boston
被験者募集中第1相
18歳以上 · 全性別 · 2026/07/09更新 · NCT07315113ClinicalTrials.govより、2026/10/05時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。